Neurology

Neuro-immunology

Questions discussed in this category

When do you consider tapering tocilizumab in patients with GCA in remission?

For patients with MS on natalizumab, at what JC virus antibody titer do you consider switching DMTs?

When do you prescribe a steroid taper after the high dose IV course for a multiple sclerosis exacerbation?

In a patient with presumed autoimmune encephalitis, would treating them with IVIG prior to getting a brain biopsy alter the pathological changes in a meaningful way?

1 Answer available

When do you consider plasmapheresis instead of (or in addition to) IV steroids for patients with acute MS exacerbation?

1 Answer available

How do you approach DMT choice in a patient with MS with a history of cancer?

Based on this review (https://doi.org/10.3389/fimmu.2019.02954), patients with MS on several DMTs may be at higher risk for certain cancers. How does ...

1 Answer available

In what patients would you consider adjunctive IVIG for Sjogren's-related neuropathy?

2 Answers available

How long do you continue immunotherapy (ie rituximab) in patients with NMDAR encephalitis with initially severe disease but a good trajectory of recovery?

1 Answer available

Would you consider spinal cord biopsy for an intramedullary cord lesion with disabling neurological deficits and no diagnosis despite a comprehensive workup?

What is the diagnostic yield and complication rate in your experience?

2 Answers available

How do you approach the treatment of SREAT (steroid-responsive encephalopathy with autoimmune thyroiditis) after initial pulse dose steroids?

1 Answer available

How often do you monitor CD-19 counts and immunoglobulin levels in MS patients on B-cell depletion therapy?

How do you approach low IgG levels on these medications?

2 Answers available

How do you approach the management of patients with one clinical demyelinating event and MOG+ antibody status?

Do you wait for a second clinical event or start immunomodulatory therapy right away?

3 Answers available

How do you approach the timing of COVID-19 vaccination for patients with multiple sclerosis on B-cell depleting therapies?

3 Answers available

How do you approach the management of acute attacks of MOGAD-associated optic neuritis?

Specifically, what do you do if there is minimal improvement with IV steroids and/or IVIG?

2 Answers available

How has your use of B-cell depleting therapy for MS changed during the COVID-19 pandemic?

Are there any specific patient populations that you are no longer routinely recommending to start B-cell depleting medications? For example, are you l...

1 Answer available

In those with a history of anti-NMDA encephalitis with identified teratoma s/p resection and clinical symptom improvement, is there a role for monitoring anti-NMDA antibody titer as a marker of disease recurrence?

1 Answer available

Do you ever check antibodies against EBV as part of a workup for MS in a patient with white matter lesions of unclear etiology on MRI?

Based on the results of the recent longitudinal analysis linking EBV infection and MS (Bjornevik et al., PMID 35025605), can negative EBV antibodies (...

1 Answer available

How do you approach the symptomatic management of Lhermitte's phenomenon in a patient with MS?

2 Answers available

How long do you maintain a patient with seropositive Neuromyelitis Optica Spectrum Disorder on disease modifying therapy?

For example, a clinically stable patient on eculizumab, do you continue it indefinitely?

1 Answer available

How do you approach transitioning MS patients from Ocrevus to Tysabri or vice versa?

1 Answer available

When is brain biopsy useful/warranted as part of the diagnostic work-up in patients with suspected primary CNS angiitis?

3 Answers available

When would you consider checking JC virus prior to initiating biologic therapy?

1 Answer available